Šoupal J, Petruželková L, Grunberger G, et al. - Researchers conducted this 3-year, nonrandomized, prospective, real-world, clinical trial to evaluate the clinical impact of four treatment strategies in adults with T1D: real-time continuous glucose monitoring (rtCGM) with multiple daily insulin injections (rtCGM+MDI), rtCGM with continuous subcutaneous insulin infusion (rtCGM+CSII), self-monitoring of blood glucose with MDI (SMBG+MDI), and SMBG with CSII (SMBG+CSII). In this trial, 94 candidates with T1D (rtCGM+MDI, n = 22; rtCGM+CSII, n = 26; SMBG+MDI, n = 21; SMBG+CSII, n = 25) were followed. In people with T1D, rtCGM was better than SMBG in decreasing A1C, hypoglycemia and other endpoints irrespective of their insulin delivery method. Findings proposed that rtCGM+MDI could be considered an equivalent but inexpensive alternative to sensor-augmented insulin pump therapy and superior to treatment with SMBG+MDI or SMBG+CSII therapy.